Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2867643 | 0.74 | LMNA (0.49) | LMNAGAANPC1USP2KMT2A | |
| SCHEMBL2493033 | 0.71 | CCR5 (0.58) | ALDH1A1NPSR1NPC1KMT2ARAB9A | |
| SCHEMBL2465826 | 0.70 | HDAC6 (0.49) | LMNAALDH1A1NPC1KMT2ATSHR | |
| SCHEMBL2699791 | 0.69 | KMT2A (0.76) | HSD11B1LMNAALDH1A1NPC1USP2 | |
| SCHEMBL2470523 | 0.69 | PKM (0.55) | HSD11B1LMNAALDH1A1GAANPSR1 | |
| SCHEMBL5132134 | 0.68 | HSD11B1 (0.62) | HSD11B1LMNAALDH1A1NPC1USP2 | |
| SCHEMBL12549973 | 0.68 | HSD11B1 (1.00) | HSD11B1LMNAALDH1A1NPC1USP2 | |
| SCHEMBL2699819 | 0.67 | LMNA (0.60) | HSD11B1LMNAALDH1A1NPC1USP2 | |
| SCHEMBL2247503 | 0.66 | RAB9A (0.81) | LMNANPC1KMT2ATSHRGFER | |
| SCHEMBL19832267 | 0.66 | PKM (0.69) | HSD11B1LMNAALDH1A1NPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | HSD11B1 4246/4885LMNA 1070/4885ALDH1A1 3941/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | HSD11B1 4246/4885LMNA 1070/4885ALDH1A1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.